Episurf Medical AB is expanding its Clinical Advisory Board
Episurf Medical AB is expanding its Clinical Advisory Board with the addition of Dr Adam Mitchell. Dr Mitchell […]
Vote for OrganoClick – Sweden’s National Champion in The European Business Awards
OrganoClick has been named National Champion for Sweden in The European Business Awards; Europe’s largest business competition, set […]
OrganoClick finalises acquisition of Biokleen Miljökemi
OrganoClick AB (publ) has finalised the acquisition of 100 % of the shares in Biokleen Miljökemi AB. With […]
Resolutions at the OrganoClick Extraordinary General Meeting
OrganoClick AB (publ) held an Extraordinary General Meeting, 19 December 2016 in Täby where the following resolutions were […]
At Serendipity, we are proud of our heritage and we embrace our serendipitous beginnings. So much so, that it is a fundamental element in our philosophy and the way we work.
For more than a decade, Serendipity has focused on transforming cutting edge technologies into products and services that bring value to the world. Ranging from environmentally friendly alternatives to existing products to novel products that pave the way and set new standards in their respective fields, we seek to build sustainable businesses with global markets.
Net Asset Value per Share
Net Asset Value
Varmt välkommen till Serendipity Ixoras årsstämma 2017. Datum: Onsdagen den 7 juni 2017 För mer information vänligen kontakta: Amin […]
Informations- och uppdateringsseminarium 1 december 2016
Varmt välkommen till Serendipity Ixoras informations- och uppdateringsseminarium som äger rum torsdagen den 1 december 2016. Platsen för […]
Quarterly update Q1 2017
The Serendipity Ixora Q1 quarterly update will be published on the company website: 2017-04-17
We identify, develop, and invest in leading innovative technologies and companies with the ability to make global impact on societal and industrial grand challenges. As such, our portfolio companies combine disruptive technologies and trends with strong and competent teams aiming for global markets.
Each new investment is evaluated in terms of market potential, scalability, distinct competitive advantage, high differentiation, strong leadership, and the ability to deliver high margins over time.
We build to keep. Therefore we have no explicit exit strategy, provided that the company continues to generate growth in line with our targets.